Proposed Information Collection for Orphan Drugs
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The FDA is calling for public comments on the information collection related to orphan drugs, which are treatments for rare diseases. This notice allows stakeholders to provide feedback on the necessity and efficiency of the current information collection process over the next 60 days.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Opportunity for public comments on orphan drug information collection
- Focus on enhancing efficiency and necessity of current processes
- 60-day comment period
Obligations
What this law requires
Companies developing orphan drugs must submit orphan drug designation requests to the FDA using Form FDA 4035.
Sponsors of orphan drugs must submit annual reports to the FDA while their products have designation status.
Companies must notify the FDA of any changes in their agents related to the orphan drug application.
Sponsors must address deficiency letters received from the FDA by submitting the required amendments.
Sponsoring organizations must provide assurance of the availability of sufficient quantities of the orphan drug.